Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There have been concerns over the rationality of prescribing practices of fixed-dose combinations (FDCs) available in India. The FDC of domperidone and pantoprazole recently emerged as a top-selling product at Janaushadhi Kendras in India.
Methods: This cross-sectional study is a part of the prescription research which was conducted under the Indian Council of Medical Research (ICMR) Task Force Project on Rational Use of Drugs at 13 tertiary healthcare centers across the countries that were part of the ICMR-Rational Use of Medicine Centres Network. An assessment of rationality for prescribing practices of FDC of domperidone and proton-pump inhibitors (PPIs) was done based on the available guidelines and evidence from the literature.
Results: In this study, 8839 outpatient prescriptions were analyzed in which FDCs with domperidone and PPI were prescribed in 481 (5.44%) cases. The FDC containing domperidone + PPI was prescribed for nausea and vomiting in 10.81% of cases. The dose was not mentioned in 55% of prescriptions; the dose of domperidone up to 30 mg/day was mentioned in 42.41% of prescriptions and more than 30 mg/day in 2.28% of prescriptions. In 89.18% of cases, it was prescribed to patients under 60 years of age.
Conclusions: This study has shown a lack of rationality in the prescribing practices in FDC containing domperidone and PPI in terms of indications, dose, frequency, duration, and administration instructions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12348719 | PMC |
| http://dx.doi.org/10.4103/ijp.ijp_744_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescribing trends of fixed-dose combination of domperidone and proton-pump inhibitor across tertiary care centers in India, is the combination rational?
Indian J Pharmacol
May 2025
Department of Health Research, Ministry of Health and Family Welfare, V. Ramalingaswami Bhawan, New Delhi, India.
Background: There have been concerns over the rationality of prescribing practices of fixed-dose combinations (FDCs) available in India. The FDC of domperidone and pantoprazole recently emerged as a top-selling product at Janaushadhi Kendras in India.
Methods: This cross-sectional study is a part of the prescription research which was conducted under the Indian Council of Medical Research (ICMR) Task Force Project on Rational Use of Drugs at 13 tertiary healthcare centers across the countries that were part of the ICMR-Rational Use of Medicine Centres Network.
Prescription pattern & adverse drug reactions of prokinetics.
Indian J Med Res
June 2019
Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital, Mumbai, India.
Background & Objectives: Prokinetics are extensively prescribed leading to several adverse events (AEs). The aim of this study was to assess the prescription pattern in patients receiving prokinetics, and characteristics of adverse drug reactions (ADRs) in an outpatient department set up in a tertiary care hospital in western India.
Methods: Patients attending outpatient departments of a tertiary care hospital and who had received prokinetic agent for at least seven days over the last one month were enrolled.
Bioequivalence study of a sustained release fixed dose combination capsule containing esomeprazole and domperidone in healthy subjects.
Arzneimittelforschung
August 2007
Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700 032 West Bengal, India.
Article Synopsis
- The study aimed to evaluate the bioavailability of two sustained release fixed-dose combination products containing esomeprazole and domperidone in 24 healthy male volunteers.
- It utilized a randomized, balanced, open-label, 2-period cross-over design, allowing participants to receive both formulations with a 7-day wash-out period in between.
- Results showed no significant differences in pharmacokinetic parameters between the products, indicating they are bioequivalent, and both were well tolerated without adverse reactions.